The investment, which is taking place in Hillerød, Denmark, will aim to create more production capacity and increase the company’s ability to meet future market demands and to continue development on its future clinical late-phase product portfolio.

The deal, valued at more than $2 billion dollars, will see Quell Therapeutics develop various T-regulatory cell therapies for AstraZeneca.

The new excipients manufacturing facility is expected to be completed in 2025.

The merger agreement states that Novartis will acquire all the shares of Chinook through a subsidiary for a price of $40 per share in cash at closing.

World leaders have set ambitious goals to respond more swiftly to the next pandemic, including the US goal to design, test, and review a new vaccine just 100 days after a pandemic declaration.

This will allow industry leaders to make and sell the product, in addition to providing more choice to pharma and biotech companies.

BIO is a powerful business development conference that can help make a lot of deals become reality.

The collaboration between Samsung Biologics and Pfizer will focus on long-term biosimilars manufacturing.

The complaint alleges that Medicaid price controls implemented in the Inflation Reduction Act will negatively impact biopharmaceutical innovation.

The document builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies.

Domino Data Lab's expanded platform includes a new project hub, additional cloud offerings, and the Model Sentry solution suite.

Under the €35 million (US$37 million) investment, MilliporeSigma will expand its sites in Glasgow and Stirling, Scotland, to increase biosafety testing for drug development and commercialization.

invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.

Lonza will gain access to R&D capabilities, including payload and site-specific linker technology, through its acquisition of ADC company, Synaffix.

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

Reimbursement for Alzheimer's medicines still will occur only with the completion of studies to support full FDA approval.

Adamis Pharmaceuticals announced the closing of its merger with DMK Pharmaceuticals on May 25, 2023.

FDA has published a new system for providing basic and essential information on patient use of drugs and certain biologic products.

The future is set to be a running theme for this year’s CPHI event, which will take place in-person at the Fira Barcelona Gran Via in Spain between 24–26 October 2023.

Despite being a relatively small nation, Switzerland is booming for biotech innovation.

Here is a small selection of some of the inspiring places to visit while in Barcelona, Spain.

Vaccine nationalism strengthens viruses and poses deadly risks for all involved.

COVID-19 has raised the specter of pandemic planning and the question of what can be done now to prevent future disaster.

Through the acquisition, Avacta gains Coris’ product portfolio consisting of diagnostic tests for respiratory, gastroenteric, and blood-borne pathogens as well as for the detection of antibiotic resistance markers.

WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.

A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.

The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.

API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.